Trials / Unknown
UnknownNCT05637983
Ultrasound-guided Femoral Puncture to Reduce Access- Related Complications After TAVR: (ACCESS-TAVR SIRIO)
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 508 (estimated)
- Sponsor
- Fondazione Toscana Gabriele Monasterio · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Recent observational data showed a marked reduction of vascular and bleeding complications by the use of ultrasound(US)-guided femoral artery puncture to gain the vascular access and guide the implantation of the Perclose ProGlide® vascular closure system. We aimed to compare in a 1:1 randomized fashion the effect of US-guided femoral puncture and Perclose ProGlide® implantation optimization vs fluoroscopy-guided puncture followed by Perclose ProGlide/ ProStyle implantation (standard approach) during TAVR.
Detailed description
Transfemoral approach has become the standard route for a transcatheter aortic valve replacement (TAVR) procedure. Despite the technology improvements, vascular complications and access-related bleeding are frequently observed after TAVR and emerge predominantly within 30 days after TAVR. Recent observational data showed a marked reduction of vascular and bleeding complications by the use of ultrasound(US)- guided femoral artery puncture to gain the vascular access and guide the implantation of the Perclose ProGlide® vascular closure system. We aimed to compare in a 1:1 randomized fashion the effect of US-guided femoral puncture and Perclose ProGlide® implantation optimization vs fluoroscopy-guided puncture followed by Perclose ProGlide/ ProStyle implantation (standard approach) during TAVR.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | US-guided femoral puncture vs Fluoroscopy-guided puncture | US-guided femoral puncture and Perclose ProGlide®/Prostyle implantation compared to Fluoroscopy-guided puncture and Perclose ProGlide®/Prostyle in TAVR |
Timeline
- Start date
- 2022-07-04
- Primary completion
- 2023-11-01
- Completion
- 2023-12-01
- First posted
- 2022-12-06
- Last updated
- 2022-12-06
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT05637983. Inclusion in this directory is not an endorsement.